We are live on ! Find out more
INFI

Infinity Pharmaceuticals, Inc.
INFI

Delisted

INFI was delisted on the 13th of September, 2023.

Back to rankings

119 hedge funds and large institutions have $762M invested in Infinity Pharmaceuticals, Inc. in 2013 Q2 according to their latest regulatory filings, with 119 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

198% more call options, than puts

Call options by funds: $26.7M | Put options by funds: $8.96M

Holders
119
Holders Change
+119
Holders Change %
–
% of All Funds
3.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
119
Increased
–
Reduced
–
Closed
–
Calls
$26.7M
Puts
$8.96M
Net Calls
+$17.7M
Net Calls Change
+$17.7M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$117M +$222M +7,174,041 New
O
2
OrbiMed
New York
$73.2M +$140M +4,520,800 New
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$52.9M +$101M +3,256,816 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$38.9M +$74M +2,392,850 New
DM
5
Deerfield Management
New York
$38.1M +$72.9M +2,354,963 New
Wellington Management Group
6
Wellington Management Group
Massachusetts
$32.6M +$62.1M +2,005,990 New
SCA
7
SAC Capital Advisors
Connecticut
$30M +$57.2M +1,847,943 New
BFA
8
BlackRock Fund Advisors
California
$29M +$55.5M +1,792,581 New
State Street
9
State Street
Massachusetts
$28.6M +$54.5M +1,760,487 New
BIT
10
BlackRock Institutional Trust
California
$21.6M +$41.3M +1,333,159 New
QF
11
QVT Financial
New York
$21.5M +$41.1M +1,326,610 New
Goldman Sachs
12
Goldman Sachs
New York
$21M +$40.1M +1,297,363 New
BA
13
BlackRock Advisors
Delaware
$20.8M +$39.8M +1,287,038 New
BB
14
BB Biotech
Switzerland
$17.6M +$33.7M +1,089,828 New
BBA
15
Baker Bros. Advisors
New York
$16.5M +$31.5M +1,016,433 New
OAM
16
Oxford Asset Management
United Kingdom
$13.2M +$25.1M +811,331 New
Ameriprise
17
Ameriprise
Minnesota
$11.9M +$22.6M +731,252 New
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$10.3M +$19.6M +632,753 New
Northern Trust
19
Northern Trust
Illinois
$8.29M +$15.8M +511,825 New
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$8.22M +$15.6M +505,631 New
ARTA
21
A.R.T. Advisors
New York
$6.85M +$13.1M +423,079 New
Jennison Associates
22
Jennison Associates
New York
$6.09M +$11.6M +375,093 New
CIP
23
Chartwell Investment Partners
Pennsylvania
$5.67M +$10.8M +350,150 New
BG
24
BlackRock Group
United Kingdom
$4.89M +$9.35M +302,045 New
EA
25
Emerald Advisers
Pennsylvania
$4.79M +$9.15M +295,741 New
1
2 3 4 5

INFI Hedge Fund Activity: Q2 2013 in Review

119 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q2 2013, worth a combined $762M.

Buyers outnumbered sellers: 119 funds opened new INFI positions and 0 closed out — a net gain of 119 holders — while 0 added to existing stakes and 0 trimmed.

  • 119 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $762M of Infinity Pharmaceuticals, Inc. stock for Q2 2013.
  • 119 funds opened new Infinity Pharmaceuticals, Inc. positions in Q2 2013 and 0 closed out, a net change of +119 holders.

Based on aggregated 13F filings for Q2 2013.